breast cancer
Conditions
Interventions
PET scan (twice)
Sponsors
Universitair Medisch Centrum Groningen
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1. Metastatic breast cancer, with at least one known metastasis outside of the liver 2. Presence of a lesion that is safely accessible for tumor biopsy (may be liver lesion) 3. Postmenopausal status defined as one of the following: a. age >=60 years b. previous bilateral oophorectomy c. age 12 months in the absence of interfering hormonal therapies (such as LH-RH agonists and ER-antagonists) d. patients age 12 months and FSH >24 U/L and LH >14 U/L e. patient age
Exclusion criteria
Exclusion criteria: 1. Use of estrogen receptor ligands, including tamoxifen, fulvestrant or estrogens, or androgen receptor ligands, during the 6 weeks before entry into the study 2. Life-expectancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The sensitivity and specificity of FDHT PET and FES PET to visualize and quantify AR- and ER-expression respectively, when compared to imunnohistochemistry on the biopsied metastasis. | — |
Secondary
| Measure | Time frame |
|---|---|
| - the heterogeneity of FDHT and FES uptake among metastases within an individual patient, as well as the inter-patient differences. - interobserver variation in PET interpretation between two independent observers from both study sites (VUMC and UMCG) | — |
Countries
Netherlands
Outcome results
None listed